Who are Escitalopram, venlafaxine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paroxetine + Venlafaxine XR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/escitalopram-venlafaxine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Escitalopram, venlafaxine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Escitalopram, venlafaxine (Escitalopram, venlafaxine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI/SNRI combination. Area: Psychiatry/Mental Health.

marketed SSRI/SNRI combination Serotonin transporter (SERT); norepinephrine transporter (NET) Psychiatry/Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Escitalopram, venlafaxine (Escitalopram, venlafaxine) — K. Lieb. This combination of escitalopram (an SSRI) and venlafaxine (an SNRI) increases serotonin and norepinephrine levels in the brain to treat depression and anxiety disorders.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Escitalopram, venlafaxine TARGET	Escitalopram, venlafaxine	K. Lieb	marketed	SSRI/SNRI combination	Serotonin transporter (SERT); norepinephrine transporter (NET)
Paroxetine + Venlafaxine XR	Paroxetine + Venlafaxine XR	Ministry of Health & Welfare, Korea	marketed	SSRI/SNRI combination	Serotonin transporter (SERT), Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI/SNRI combination class)

K. Lieb · 1 drug in this class
Ministry of Health & Welfare, Korea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Escitalopram, venlafaxine — Competitive Intelligence Brief. https://druglandscape.com/ci/escitalopram-venlafaxine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab